Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)
- Conditions
- Interventions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 882
- Registration Number
- NCT00144170
- Locations
- 🇲🇽
1182.48.5202 Hospital Lopez Mateos, Mexico, Mexico
🇵🇹1182.48.3505 Hospital Egas Moniz, Lisboa, Portugal
🇲🇽1182.48.5201 Centro Médico La Raza IMSS, Mexico, D.F., Mexico
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5993
- Registration Number
- NCT00144339
- Locations
- 🇺🇸
205.235.3781 Boehringer Ingelheim Investigational Site, San Diego, California, United States
🇺🇸205.235.3782 Boehringer Ingelheim Investigational Site, Fredericksburg, Virginia, United States
🇺🇸205.235.3744 Boehringer Ingelheim Investigational Site, Danville, Virginia, United States
12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 224
- Registration Number
- NCT00144196
- Locations
- 🇸🇪
Boehringer Ingelheim Investigational Site, Uppsala, Sweden
🇸🇪Jakobsbergs sjukhus, Birgittavagen 4, Jarfalla, Sweden
🇸🇪KvartersAkuten, Timmermansgatan 26, Lule?, Sweden
An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT00144261
- Locations
- 🇳🇱
1100.1426.02 Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
🇳🇱1100.1426.01 Academic Medical Centre, Amsterdam, Netherlands
🇬🇧1100.1426.44001 Boehringer Ingelheim Investigational Site, London, United Kingdom
Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2014-03-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 246
- Registration Number
- NCT00144300
- Locations
- 🇺🇸
248.538.00010 Boehringer Ingelheim Investigational Site, New York, New York, United States
🇺🇸248.538.00013 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States
🇺🇸248.538.00006 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 51
- Registration Number
- NCT00144248
- Locations
- 🇺🇸
Albany Medical College, MC 142, Albany, New York, United States
🇫🇷Hopital Pitie Salpetriere, Paris, France
🇺🇸Boehringer Ingelheim Investigational Site, Providence, Rhode Island, United States
A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 250
- Registration Number
- NCT00144326
- Locations
- 🇨🇦
1796 Summer Street, Halifax, Nova Scotia, Canada
🇨🇦Kingston General Hospital, Kingston, Ontario, Canada
🇨🇦Montreal Chest Institute of the Royal Victoria Hospital, Montreal, Quebec, Canada
A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate Hypertension
- Conditions
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 31
- Registration Number
- NCT00133185
- Locations
- 🇨🇳
Machay Memorial Hospital, Taipei, Taiwan
Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)
- Conditions
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 345
- Registration Number
- NCT00133198
- Locations
- 🇺🇸
Metrohealth Medical Center, Cleveland, Ohio, United States
🇺🇸Mid America NeuroScience Institute, Lenexa, Kansas, United States
🇺🇸HealthQuest Clinical Trials Research, San Diego, California, United States
Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients
- Conditions
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 11
- Registration Number
- NCT00129038
- Locations
- 🇮🇪
9.169.02 St. James' Hospital, Dublin 8, Ireland
🇮🇪9.169.01 Dept of Clinical Pharmacology, Dublin 9, Ireland